oral glp-1 medication The Next Wave of Obesity Treatment: Medications Oral GLP-1 Orforglipron Is Approved

PMID 32002850

All three have filed lawsuits that blame the popular class of weight-loss drugs known as GLP-1 receptor agonists, which include Ozempic, Wegovy and Mounjaro, and theyre part of a growing number of lawsuits alleging the drugs makers failed to sufficiently warn of the risk of certain severe injuries

When levels drop, health problems follow

In a nutshell, that allows compounders to make compounds in small quantities for patients whose needs are not met by a standard formulation

Some patients may experience mild side effects such as injection-site irritation, headaches, temporary water retention, or changes in appetite